Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age21+
SponsorCassandra Kisby

About this trial

Pelvic organ prolapse (POP) is a condition characterized by descent of vaginal walls, uterus and cervix, or the perineum and causes a sensation of vaginal bulge and pelvic pressure. Millions of women in the United States are affected, and the number is expected to rise significantly in the coming decades. Current treatments either involve conservative measures or surgery. Surgery may lead to changes in vaginal topography and scar tissue, both of which impact sexual function. There are no treatment options that restore vaginal tissue strength and preserve, even optimize, sensation and blood flow to the vagina. This project will evaluate the use of poly-L-lactic acid (PLLA), an FDA-approved biostimulant for dermatologic use with an expansive safety profile over the past decade, in the treatment of anterior wall POP and its impact on sexual function. Our study will compare intravaginal injection of PLLA vs. placebo in women with stage 2 cystocele and investigate safety and preliminary efficacy of PLLA. Prior study of regenerative biologics for the vulva and vagina have shown great promise, but use of these has not been explored for POP. This randomized controlled trial has the potential to shift the paradigm of prolapse management from surgical reconstruction to regeneration. This shift will prevent the risks of surgery and has the potential to improve sexual function and quality of life by resolving POP.

Eligibility criteria

Qualifiers

Age > 21

Stage II POP of anterior vaginal wall (Ba ≥ -1)

Symptomatic bulge symptoms

Positive response to PFDI-20 question 3: Do you usually have a bulge or something falling out that you can see or feel in the vaginal area?

Disqualifiers

Concurrent apical or posterior prolapse > stage 1

Prior pelvic radiation

Previous vaginal reconstructive surgery (Except total vaginal hysterectomy or sling)

History of chronic vaginal infections (ex. Sexually transmitted infection or bacterial vaginosis)

Trial design

Treatments tested in this trial

  • Poly-L-Lactic Acid (Sculptra) injection
  • Placebo injection (sterile water)

Treatment groups

20 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Cassandra Kisby

Lead sponsor

Duke University

Sponsor institution

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Collaborator